Development of Highly Selective 1,2,3-Triazole-containing Peptidic Polo-like Kinase 1 Polo-box Domain-binding Inhibitors

Article abstract of DOI:10.3390/molecules24081488

Members of the polo-like kinase (Plk) family of serine/threonine protein kinases play crucial roles in cell cycle regulation and proliferation. Of the five Plks (Plk1–5), Plk1 is recognized as an anticancer drug target. Plk1 contains multiple structural components that are important for its proper biological function. These include an N-terminal catalytic domain and a C-terminal non-catalytic polo-box domain (PBD). The PBD binds to phosphothreonine (pT) and phosphoserine-containing sequences. Blocking PBD-dependent interactions offers a potential means of down-regulating Plk1 function that is distinct from targeting its ATP-binding site. Previously, we demonstrated by tethering alkylphenyl chains from the N(π)-position of the His residue in the 5-mer PLHSpT, that we were able to access a hydrophobic “cryptic” binding pocket on the surface of the PBD, and in so doing enhance binding affinities by approximately 1000-fold. More recently, we optimized these PBD-ligand interactions using an oxime ligation-based strategy. Herein, using azide-alkyne cycloaddition reactions, we explore new triazole-containing PBD-binding antagonists. Some of these ligands retain the high PBD-binding affinity of the parent peptide, while showing desirable enhanced selectivity for the PBD of Plk1 relative to the PBDs of Plk2 and Plk3.

Full text of DOI:10.3390/molecules24081488

molecules
Article
Development of Highly Selective 1,2,3-Triazole-
containing Peptidic Polo-like Kinase 1 Polo-box
Domain-binding Inhibitors
Xue Zhi Zhao * , Kohei Tsuji, David Hymel and Terrence R. Burke Jr. *
Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of
Health, Frederick, MD 21702, USA; kohei.tsuji@nih.gov (K.T.); hymel.david@gmail.com (D.H.)
* Correspondence: xuezhi.zhao@nih.gov (X.Z.Z.); burkete@nih.gov (T.R.B.J.);
Tel.: +1-301-846-5907 (X.Z.Z.); +1-301-846-5906 (T.R.B.J.)
ꢀꢁꢂꢀꢃꢄꢅꢆꢇ
ꢀꢁꢂꢃꢄꢅꢆ
Academic Editors: Henry Mosberg, Tomi Sawyer and Carrie Haskell-Luevano
Received: 29 March 2019; Accepted: 14 April 2019; Published: 16 April 2019
Abstract: Members of the polo-like kinase (Plk) family of serine/threonine protein kinases play crucial
roles in cell cycle regulation and proliferation. Of the five Plks (Plk1–5), Plk1 is recognized as an
anticancer drug target. Plk1 contains multiple structural components that are important for its proper
biological function. These include an N-terminal catalytic domain and a C-terminal non-catalytic
polo-box domain (PBD). The PBD binds to phosphothreonine (pT) and phosphoserine-containing
sequences. Blocking PBD-dependent interactions offers a potential means of down-regulating Plk1
function that is distinct from targeting its ATP-binding site. Previously, we demonstrated by tethering
alkylphenyl chains from the N(π)-position of the His residue in the 5-mer PLHSpT, that we were
able to access a hydrophobic “cryptic” binding pocket on the surface of the PBD, and in so doing
enhance binding affinities by approximately 1000-fold. More recently, we optimized these PBD-ligand
interactions using an oxime ligation-based strategy. Herein, using azide-alkyne cycloaddition
reactions, we explore new triazole-containing PBD-binding antagonists. Some of these ligands retain
the high PBD-binding affinity of the parent peptide, while showing desirable enhanced selectivity for
the PBD of Plk1 relative to the PBDs of Plk2 and Plk3.
Keywords: Plk1; selectivity; polo-box domain; peptide; triazole
1. Introduction
Members of the polo-like kinase (Plk) family play crucial roles in mammalian cell cycle regulation
and proliferation [1]. Proper function of Plks 1–4 requires the coordinated phosphorylation of serine
and threonine residues by N-terminal kinase domains (KDs) as well as engagement of protein-protein
interactions (PPIs) with phosphoserine (pS)/phosphothreonine (pT)-containing sequences by means
of their C-terminal polo-box domains (PBDs) [
more distantly related [ ]. The association of Plk1 over-expression with neoplastic transformation
and tumor aggressiveness has defined it as a potentially promising anticancer molecular target [ ].
2]. While Plks 1–3 share significant homology, Plk4 is
3,4
5–8
To date, issues of collateral cytotoxicity have arisen for Plk1 kinase inhibitors. This is in part due to
a lack of selectivity arising from the general homology among kinase catalytic domains. Given the
uniqueness of PBDs to the Plk family, targeting PBD-mediated PPIs may allow down-regulation of Plk1
function with greater kinome selectivity than with inhibitors directed at the KD. However, Plk2 and
Plk3 have roles in checkpoint-mediated cell-cycle arrest and maintenance of genetic stability, and they
may serve as potential tumor suppressors [3,4,9]. Therefore, in developing PBD-binding inhibitors, it is
desirable that they are selective for Plk1 versus Plk2 and Plk3. Because of the high homology among
Molecules 2019, 24, 1488; doi:10.3390/molecules24081488
www.mdpi.com/journal/molecules

Molecules 2019, 24, 1488
2 of 15
the PBDs of Plks 1–3, achieving selectivity for the PBD of Plk1 presents an important and challenging
objective [7,8,10–13].
In designing Plk1 PBD-binding inhibitors, we have previously started with the polo-box interacting
protein 1 (PBIP1)-derived 5-mer PLHSpT (
enhancement of Plk1 PBD-binding affinity can be achieved by appending alkylphenyl groups from
the His N( )-position (as exemplified by 2a) [15]. A crystal structure of PBD-bound 2a revealed that
1) (Figure 1) [7,14]. We found that up to 1000-fold
π
the alkylphenyl group is situated within a hydrophobic aromatic box defined by residues Y417, Y421,
Y481, L478, F482 and Y485. This may be considered as being “cryptic” in nature, since it is revealed
by rotation of the Y481 side chain [15]. We have reached the pocket from parent
approaches, including tethering alkylphenyl groups from the Pro residue [16], an amino-terminal
N-alkyl Gly residue [17] and from macrocyclic variants [18 19]. The pocket can also be accessed
1 by a variety of
,
from more extended peptides, such as the amino-terminal Phe residue of the PBIP1-derived peptide
FDPPLHSpTA [20–22].
Figure 1. The polo-box interacting protein 1 (PBIP) pT78-derived peptide
1 and related derivatives
discussed in the text.
The ability to engage the cryptic pocket has been a critical element of the highest affinity
PBD-binding ligands reported to date. Within this context, the pT-2 position arguably represents the
most efficient position from which to achieve this access, since it is the most proximal residue to the
critical “SpT” recognition motif [23]. By examining a variety of non-proteinogenic amino acid residues
at the pT-2 position, we found that the highest affinities were shown by those peptides having alkylation
at the His-N(
the isomeric His-N(
interactions has been made difficult due to the tediousness of preparing individual His-N(
π
) position, which provided approximately 50-fold higher affinity than alkylation at
)position (peptides 2a and 4a, respectively, Figure 1) [24]. Yet, optimizing these
)-alkyl
τ
π
analogs. In response to these challenges, we employed an oxime-based post-solid phase peptide
diversification strategy that allowed us to screen more than 80 analogs. Ligands such as 2b resulted,
which show enhanced Plk1 PBD affinity or selectivity relative to parent 2a [25,26].
The utility of 1,2,3-triazoles for introducing conformational constraint in peptidomimetic chemistry
has been reported [27–35]. A triazole replacement of the imidazole ring in His has been used to
prepare constrained His mimics [36]. More recently, triazole-based His mimetics bearing long-chain
alkylphenyl groups have been examined within the context of non-peptidic Plk1 PBD inhibitors [37].
However, the best of these constructs showed Plk1 PBD-binding affinities that were 5- to 18-fold less
potent than
the use of on-resin azide-alkyne cycloaddition reactions to introduce 1,2,3-triazole functionality into
potent lead Plk1 PBD inhibitors based on 2a 15] and 2b 25 26]. The triazole rings were intended either
to induce conformational constraint (3a 3d) or to serve as a His mimetic (4b). This work has allowed
1 (which itself exhibits 3-orders of magnitude less affinity than 2a) [37]. Herein, we report
[
[
,
–

Molecules 2019, 24, 1488
3 of 15
us to prepare in facile fashion, new ligands that retain the high Plk1 PBD-binding affinity of the parent
peptide, while enhancing selectivity for the PBD of Plk1 relative to the PBDs of Plk2 and Plk3.
2. Results and Discussion
2.1. Synthesis
Benzylazides 9a
available benzyl bromides 8a
three steps from commercially available 2,6-difluorobenzylaldehyde (
group in by phenol afforded 25], which was then reduced with sodium borohydride to yield
alcohol . Application of the Appel reaction [38] using carbon tetrabromide and triphenylphosphine
afforded bromide 8d (Scheme 1).
–
9d were prepared using SN2 reactions of sodium azide with commercially
8c and freshly prepared 8d (Scheme 1). Bromide 8d was synthesized in
). Displacement of one fluoro
–
5
5
6 [
7
Scheme 1. Preparation of azides 9a
–9d. Reagents and Conditions: i) PhOH, K2CO3, dimethylacetamide
(DMA), 165 ◦C; ii) NaBH4, MeOH; iii) CBr4, PPh3, CH3CN; iv) NaN3, acetone:H2O (5:1).
The protected N(π
)-alkyne-labeled His derivative 11 was easily obtained by alkylating Nα-Fmoc-
Nτ-Trt-l-His 2,4-dimethoxylbenzyl ester (10) [25] with hex-5-yn-1-ol according to our previously
reported methodology [39]. This was then used to prepare the fully protected alkyne-containing
peptide 12 on NovaSyn® TGR resin by standard Fmoc solid-phase peptide synthesis (SPPS) protocols
in N-methylpyrrolidone (NMP) (Scheme 2). Resin 12 was subsequently subjected to Cu(I) catalyzed
[3 + 2] cycloaddition reactions (on-resin CuAAC) with the related benzylazides 9a
The regioselective CuAAC reaction has been an important advance that provides a reliable means
for selectively assembling 1,4-disubstituted 1,2,3-triazoles [40 42]. The resins were cleaved using a
cocktail solution of TFA:H2O:triisopropylsilane (TIS) (95:2.5:2.5) to provide the triazole-containing
–9d (Scheme 2).
–
peptides 3a–3d following HPLC purification. Alkyne-labeled peptide 13 was prepared by cleavage of
12 directly.
Scheme 2. Preparation of triazole-containing peptides 3a–3d and alkyne-labeled peptide 13. Reagents

Molecules 2019, 24, 1488
andConditions: i)CH
4 of 15
≡
C(CH2)4OH,trifluoromethanesulfonicanhydride(Tf2O),N,N-diisopropylethylamine
(DIEA), dichloromethane (DCM); ii) trifluoroacetic acid (TFA), triisopropylsilane (TIS); iii) Bn-N3 (9a
–9d),
CuI, l-ascorbic acid, dimethylformamide (DMF):BuOH:Pyr (3:5:2); iv) TFA:H2O:TIS (95:2.5:2.5).
Preparation of the triazole-based His mimetic containing peptide 4b and alkyne-labeled peptide
17 are shown in Scheme 3. Protected 15 was prepared on NovaSyn® TGR resin using commercially
available Fmoc-l-propargylglycine (14) and standard Fmoc SPPS protocols. Cleavage of resin 15 and
HPLC purification yielded alkyne-containing peptide 17 directly. Alternatively, an on-resin CuAAC
reaction of 15 with phenyloctylazide 16 followed by resin cleavage gave peptide 4b after HPLC
purification (Scheme 3).
Scheme 3. Preparation of triazole-containing peptides 4b and alkyne-labeled peptide 17. Reagents
and Conditions: i) Ph(CH2)8N3 (16), CuI, l-ascorbic acid, DMF:BuOH:Pyr (3:5:2); ii) Cp*RuCl(PPh3)2,
Ph(CH2)8N3 (16), DMF; iii) TFA:H2O:TIS (95:2.5:2.5).
It was our original intent to prepare both 1,4-substituted and 1,5-substituted triazoles as mimetics
of the isomeric N(
τ
)- and N(
π
)-alkylated His analogs, respectively. As stated above, the CuAAC
42].
reaction provides a reliable means for selectively assembling 1,4-disubstituted 1,2,3-triazoles [40
–
Accordingly, when we subjected resin-bound alkyne-containing peptide 15 to CuAAC-catalyzed
cycloaddition with phenyloctylazide 16, we obtained a peptide following resin cleavage and HPLC
purification, whose structure we assigned as 4b (Scheme 3). Alternatively, the ruthenium-catalyzed
cycloaddition of azides with alkynes (RuAAC) has been reported to regioselectively yield
1,5-disubstituted 1,2,3-triazoles [43,44]. Based on this, we used the on-resin RuAAC-catalyzed
[3 + 2] cycloaddition reaction of the alkyne group of resin 15 and azide 16 with the expectation of
obtaining the isomeric 1,5-substituted triazole 18 (Scheme 3). However, the resulting peptide was
identical in all respects with peptide 4b (1H-, 13C- and 31P-NMR). At this point, a search of the literature
revealed that a simple method has been reported, which permits reliable establishment of triazole
regio-substitution based on chemical shifts in one-dimensional 13C-NMR spectra [45]. The C5 signal of
1,4-disubstituted-1H-1,2,3-triazoles characteristically appears at approximately
δ = 120 ppm, while
the C4 signal of 1,5-disubstituted-1H-1,2,3-triazoles is usually found at = 133 ppm. In our case,
δ
the products obtained from both CuAAC and RuAAC chemistries provided a diagnostic signal of
δ = 123.04 ppm, indicating that the 1,4-substituted triazole (4b) was obtained in both cases.
2.2. Biological Evaluation
We employed fluorescence polarization (FP) assays to evaluate binding affinities against the
isolated PBDs of Plk1, Plk2 and Plk3 (Table 1, Figure S1 in Supplementary Material). Compared with
the parent peptide
1 (IC50 = 650 nM) replacement of the His imidazole ring with an alkyne group
resulted in an approximate 2-fold loss of Plk1 PBD-binding affinity (17, IC50 = 1000 nM, Table 1).
Interestingly, peptide 13 (IC50 = 1100 nM) showed equivalent Plk1 PBD-binding affinity, in spite of the
fact that it included a hex-5-yn-1-yl moiety at the His N(π)-position. This group would be expected to

Molecules 2019, 24, 1488
5 of 15
partially engage the hydrophobic channel leading to the cryptic pocket. We have previously shown that
peptides 2a and 2b exhibit binding affinities (IC50 values of approximately 15 nM) that are significantly
more potent than parent peptide
1 (approximately 650 nM) [25,26]. Peptides 2a and 2b show more
than 10-fold selectivity for Plk1 relative to Plk2 and approximately 70-fold and 20-fold over Plk3,
respectively (Table 1).
Table 1. Inhibitory potencies of peptides containing different linkers using a fluorescence polarization
(FP) assay. Polo-like kinase (Plk), polo-box domain (PBD).
IC50 (nM)
Peptide
R
PLK1 PBD
PLK2 PBD
PLK3 PBD
1 i
17
ND iv
650 ± 39
ND
1000 ± 140
1100 ± 45
ND
ND
ND
ND
13
2a ii
15 ± 0.94
15 ± 0.33
220 ± 15
180 ± 14
1100 ± 230
450 ± 87
2b iii
3a
3b
3c
110 ± 6.6
100 ± 19
130 ± 9.8
ND
ND
ND
ND
ND
ND
3d
25 ± 1.6
5900 ± 420
690 ± 20
9900 ± 2200
3400 ± 130
4b
17 ± 0.17
i
See reference [14]; ii See reference [15]; iii See references [25,26]; iv Not determined.

Molecules 2019, 24, 1488
6 of 15
Peptides 3a
)-position by –(CH2)4– chains. Similar to 2a and 2b, this results in a total chain extension of 8-units
between the His N( )-nitrogen and the terminal aryl group. We had previously shown that this is an
optimal length by examining a series of sequentially lengthened tethers [15]. Introducing a 4-fluoro
substituent (3b, IC50 = 100 nM, Table 1) or 3-chloro-4-fluoro substituents (3c IC50 = 130 nM, Table 1)
–3d represent a series of analogs having 1,4-substituted triazoles tethered from the His
N(π
π
,
were intended to potentially enhance interactions with the hydrophobic cryptic pocket. However,
these did not significantly alter affinity relative to 3a. The reasons for this are not clear. Although
peptide 3a was designed to mimic peptide 2a, it shows an approximate 8-fold relative loss of Plk1
PBD-binding affinity (3a, IC50 = 110 nM, Table 1). In contrast to the marked loss of affinity incurred
by introducing the triazole ring to 2a, the triazole-containing mimetic of 2b showed good retention
of Plk1 PBD-binding (3d, IC50 = 25 nM). While peptides 3a–3c contain a single tethered phenyl ring,
peptide 3d has a bis-aryl system. The greater extension afforded by this latter arrangement may
permit better retention of binding interactions with the cryptic pocket than is afforded by peptides
have a single phenyl ring. Importantly, 3d showed extremely high selectivity for Plk1 relative to Plk2
(IC50 = 5900 nM) and Plk3 (IC50 = 9900 nM) (Table 1).
In contrast to peptides 3a–3d, where triazole rings were inserted into His-N(π)-tethered chains
to potentially induce conformational constraint proximal to the cryptic binding pocket, peptide 4b
represents a triazole mimetic of the His imidazole ring. In our previous efforts to access the cryptic
pocket using a variety of amino acid derivatives at the pT-2 position, the highest affinities were
obtained using His residues, with alkylation at the His-N(
preferred to alkylation at the isomeric His-N( ) position (4a, Figure 1) [24]. In spite of the fact that
the 1,4-triazole substitution pattern of 4b does not appear to optimally replicate the geometry of the
His-N( )-1,2-imidazole pattern shown by 2a, its Plk1 binding affinity (IC50 = 17 nM) equals that of
π) position (2a, Figure 1) being significantly
τ
π
2a (Table 1). The Plk1 PBD selectivity of 4b is slightly better than 2a against the Plk2 and Plk3 PBDs
(690 nM and 3400 nM, respectively).
It is known that auto-inhibitory interdomain interactions between the KD and PBD can result in
decreased potencies in assays that employ full-length Plk1 relative to assays that use isolated PBD
preparations, which lack a KD component [23]. The selectivity data shown in Table 1 were obtained
using fluorescence polarization assays with isolated PBDs. In contrast, Table 2 shows binding data
from an ELISA assay employing full-length Plk1 (Figure S2 in Supplementary Material). Peptides
possessing His-N(π)-tethered chains showed an approximate order-of-magnitude potency reduction
in the full-length assay relative to the isolated PBD assay (27-fold and 19-fold reductions for 2a and
2b, respectively). However, triazole-containing peptides experienced significantly greater losses of
inhibitory potency (160-fold for 4b and 480-fold for 3d). The larger differences may indicate a reduced
ability of these peptides to effectively relieve auto-inhibition or to engage the PBD cryptic pocket in the
full-length construct.
Although there are no crystals structure of full-length Plk1, which might clarify the mechanisms of
autoinhibition, a co-crystal structure of Map205-stabilized isolated Plk1 KD and PBD has been solved
(PDB accession code: 4J7B) [46]. In this structure the KD is situated on the face of the PBD opposite the
phosphopeptide-binding site. In such an orientation, the KD displaces downward an extended loop
of the PBD (residues 490–510) from where it is typically observed in isolated PBD crystal structures
with bound phosphopeptides. This conformational change prevents the loop from participating in an
extensive network of water-mediated hydrogen bonds with the peptide phosphate group. This may be
related to the ability of the KD to inhibit ligand binding to the PBD in full-length Plk1. It is unclear
from this how access to the cryptic pocket would be adversely impacted in full-length Plk1 or why the
triazole-containing peptides would be more sensitive to these effects. However, it is intriguing that
this loop originates from the
cryptic binding pocket.
αB helix (residues 470–489), which forms an important component of the

Molecules 2019, 24, 1488
7 of 15
Table 2. PBD-binding affinities of peptides against full-length Plk1 using an ELISA assay.
Peptide
2a i
2b ii
IC50 (nM)
400 ± 32 (27×) iii
290 ± 6.7 (19×)
12000 ± 2100 (480×)
2700 ± 190 (159×)
3d
4b
See reference [15]; ii See references [25,26]; iii Fold-change relative to isolated PBD value.
i
3. Experimental Section
3.1. Synthesis
3.1.1. General Procedures
As previously reported [26], proton (1H) and carbon (13C) NMR spectra were recorded on a Varian
400 MHz spectrometer or a Varian 500 MHz spectrometer (Varian, Palo Alto, CA, USA) and are reported
in ppm relative to tetramethylsilane (TMS) and referenced to the solvent in which the spectra were
collected. Solvent was removed by rotary evaporation under reduced pressure and anhydrous solvents
were obtained commercially and used without further drying. Purification by silica gel chromatography
was performed using Combiflash instruments (Telenyde ISCO, Lincoln, NE, USA) with EtOAc-hexanes
or CH2Cl2-MeOH solvent systems. Preparative high pressure liquid chromatography (HPLC) was
conducted using a Waters Prep LC4000 system (Waters, Milford, MA, USA) having photodiode array
detection and C18 columns (catalogue No. 00G4436-P0-AX, 250 mm × 21.2 mm 10 µm particle size,
110 Å pore, Phenomenex, Torrance, CA, USA) at a flow rate of 10 mL/min. Binary solvent systems
consisting of A = 0.1% aqueous TFA and B = 0.1% TFA in acetonitrile were employed with gradients
as indicated. Products were obtained as amorphous solids following lyophilization. Electrospray
ionization-mass spectra (ESI-MS) were acquired with an Agilent LC/MSD system (Agilent, Santa
Clara, CA, USA) equipped with a multimode ion source. High resolution mass spectrometric (HRMS,
ThermoFisher Scientific, Grand Island, NY, USA) were acquired by LC/MS-ESI with a LTQ-Orbitrap-XL
at 30 K resolution.
3.1.2. Synthesis of 2-Fluoro-6-phenoxybenzaldehyde (6)
According to the literatures [25,47], to a solution of 2,6-difluorobenzaldehyde (5) (11 mL, 102 mmol)
and phenol (9.6 g, 102 mmol) in dimethylacetamide (DMA) (50 mL) was added potassium carbonate
(14 g, 102 mmol) and the mixture was heated and refluxed (165 ◦C, 2 h). The mixture was cooled to room
temperature, diluted with H2O (100 mL), extracted with CH2Cl2 and the combined organic extract was
dried (Na2SO4) and concentrated. The resulting residue was purified by silica gel chromatography
1
to afford product
6
as a colorless oil (14.1 g, 64% yield). H-NMR (400 MHz, CDCl3)
δ
10.52 (s, 1H),
7.47–7.40 (m, 3H), 7.23 (t, J = 7.4 Hz, 1H), 7.09 (dd, J = 8.6, 1.2 Hz, 2H), 6.89–6.85 (m, 1H), 6.66 (d,
J = 8.5 Hz, 1H). 13C-NMR (101 MHz, CDCl3)
δ
186.79 (1C, d, J = 2.3 Hz), 162.90 (1C, d, J = 263.4 Hz),
160.50 (1C, d, J = 5.2 Hz), 155.63, 135.73 (1C, d, J = 11.6 Hz), 130.19 (2C), 124.90, 119.85 (2C), 116.03 (1C,
d, J = 9.5 Hz), 113.48 (1C, d, J = 3.7 Hz), 110.81 (d, J = 21.2 Hz). ESI-MS m/z: 239.0 [M + Na+].
3.1.3. Synthesis of (2-Fluoro-6-phenoxyphenyl)methanol (7)
To a solution of 2-fluoro-6-phenoxybenzaldehyde (6) (5.9 g, 27 mmol) in MeOH (100 mL) was
added sodium borohydride (1.0 g, 27 mmol) portion-wise at 0 ◦C and the mixture was stirred (0 ◦C,
30 min), then concentrated. The resulting residue was partitioned between EtOAc and brine, dried
(Na2SO4), concentrated and purified by silica gel chromatography to afford product
7
as a colorless
1
oil (5.7 g, 96% yield). H-NMR (500 MHz, CDCl3)
δ 7.40–7.37 (m, 2H), 7.23–7.16 (m, 2H), 7.06–7.04
(m, 2H), 6.86 (t, J = 8.9 Hz, 1H), 6.66 (d, J = 8.3 Hz, 1H), 4.85 (s, 2H).13C-NMR (126 MHz, CDCl3)
δ

Molecules 2019, 24, 1488
8 of 15
161.70 (1C, d, J = 247.3 Hz), 156.95 (1C, d, J = 7.4 Hz), 156.62, 129.98 (2C), 129.57 (1C, d, J = 10.5 Hz),
124.02, 119.41 (1C, d, J = 18.0 Hz), 119.04 (2C), 113.77 (1C, d, J = 3.3 Hz), 110.48 (1C, d, J = 22.6 Hz),
54.02 (1C, d, J = 5.1 Hz).
3.1.4. Synthesis of 2-(Bromomethyl)-1-fluoro-3-phenoxybenzene (8d)
According to the literature [38], triphenylphosphine (10 g, 39 mmol) was added to a solution of
(2-fluoro-6-phenoxyphenyl)-methanol (
7
) (5.7 g, 26 mmol) in acetonitrile (70 mL) and the suspension
◦
was cooled to 0 C and carbon tetrabromide (13 g, 39 mmol) was added. The suspension turned
to a clear brown solution and then to a white suspension after 2 min. The reaction suspension was
stirred (room temperature, 30 min), then diluted with EtOAc and the organic phase was concentrated
and purified by silica gel chromatography to provide product 8d as a colorless oil (7.4 g, 99% yield).
1H-NMR (500 MHz, CDCl3)
1H), 6.63 (d, J = 8.4 Hz, 1H), 4.70 (d, J = 1.3 Hz, 2H). 13C-NMR (126 MHz, CDCl3)
δ
7.43–7.40 (m, 2H), 7.23–7.19 (m, 2H), 7.12–7.09 (m, 2H), 6.86 (t, J = 9.2 Hz,
161.56 (1C, d,
δ
J = 250.5 Hz), 156.91 (1C, d, J = 6.4 Hz), 156.34, 130.16 (1C, d, J = 10.5 Hz), 129.98 (2C), 124.30, 119.61
(2C), 117.10 (1C, d, J = 17.2 Hz), 113.42 (1C, d, J = 3.2 Hz), 110.11 (1C, d, J = 21.6 Hz), 20.10 (1C, d,
J = 5.4 Hz).
3.1.5. General Procedure A for the Synthesis of Azides 9a–9d and 16
To a solution of bromides 8a–8d or commercially available (8-bromooctyl)benzene (7.0 mmol) in
acetone (10 mL) and H2O (2.0 mL) was added sodium azide (1.8 g, 28 mmol) and the mixture was
stirred (55 ◦C, 15 h). The reaction was quenched by the addition of H2O, extracted with Et2O and the
combined organic phase was washed with brine, dried (Na2SO4), concentrated and purified by silica
gel chromatography to provide the target azides 9a–9d, and 16.
3.1.6. Synthesis of (Azidomethyl)benzene (9a)
According to the literature [48], treatment of (bromomethyl)benzene (8a) [48] as outlined in
general procedure A provided title compound 9a as a colorless oil (57% yield). ESI-MS m/z: 106.1
(MH+ − N2).
3.1.7. Synthesis of 1-(Azidomethyl)-4-fluorobenzene (9b)
Treatment of 1-(bromomethyl)-4-fluorobenzene (8b) as outlined in general procedure A provided
1
the title compound 9b as a colorless oil (82% yield). H-NMR (500 MHz, CDCl3)
5.4 Hz, 2H), 7.10 (t, J = 8.6 Hz, 2H), 4.34 (s, 2H). ESI-MS m/z: 124.1 (MH+ − N2).
δ 7.32 (dd, J = 8.4,
3.1.8. Synthesis of 4-(Azidomethyl)-2-chloro-1-fluorobenzene (9c)
Treatment of 4-(bromomethyl)-2-chloro-1-fluorobenzene (8c) as outlined in general procedure A
1
provided the title compound 9c as a colorless oil (49% yield). H-NMR (500 MHz, CDCl3)
δ
7.40 (dd,
J = 6.9, 2.1 Hz, 1H), 7.22 (ddd, J = 7.0, 4.7, 2.1 Hz, 1H), 7.18 (t, J = 8.5 Hz, 1H), 4.34 (s, 2H). 13C-NMR
(126 MHz, CDCl3) δ157.94 (d, J = 249.9 Hz), 132.53 (d, J = 4.0 Hz), 130.37, 127.85 (d, J = 7.3 Hz), 121.46
(d, J = 18.0 Hz), 116.96 (d, J = 21.4 Hz), 53.54. ESI-MS m/z: 158.1 (MH+ − N2)
3.1.9. Synthesis of 2-(Azidomethyl)-1-fluoro-3-phenoxybenzene (9d)
Treatment of 2-(bromomethyl)-1-fluoro-3-phenoxybenzene (8d) as outlined in general procedure
1
A provided the title compound 9d as a colorless oil (58% yield). H-NMR (400 MHz, CDCl3)
δ 7.79
(t, J = 7.9 Hz, 2H), 7.67–7.63 (m, 1H), 7.61–7.57 (m, 1H), 7.47–7.45 (m, 2H), 7.28 (t, J = 8.6 Hz, 1H),
7.05 (d, J = 8.4 Hz, 1H), 4.91 (s, 2H). 13C-NMR (101 MHz, CDCl3)
δ
162.04 (d, J = 248.7 Hz), 157.26
(d, J = 7.0 Hz), 156.14, 130.29 (d, J = 10.5 Hz), 130.00 (2C), 124.30, 119.47 (2C), 114.17 (d, J = 18.2 Hz),
113.12 (d, J = 3.3 Hz), 110.09 (d, J = 22.2 Hz), 42.55 (d, J = 4.0 Hz). ESI-MS m/z: 216.1 (MH+ − N2).

Molecules 2019, 24, 1488
9 of 15
3.1.10. Synthesis of (8-Azidooctyl)benzene (16)
Treatment of commercially available (8-bromooctyl)benzene as outlined in general procedure A
1
provided the title compound 16 as a colorless oil (68% yield). H-NMR (400 MHz, CDCl3)
δ 7.32–7.28
(m, 2H), 7.22–7.18 (m, 3H), 3.28 (t, J = 7.0 Hz, 2H), 2.64 (t, J = 7.7 Hz, 2H), 1.66–1.58 (m, 4H), 1.41–1.33
(m, 8H). 13C-NMR (101 MHz, CDCl3)
δ 142.82, 128.39 (2C), 128.23 (2C), 125.59, 51.49, 35.96, 31.45, 29.34,
29.19, 29.08, 28.84, 26.71. ESI-MS m/z: 204.2 (MH+ − N2).
3.1.11. Synthesis of Nα-(((9H-Fluoren-9-yl)methoxy)carbonyl)-Nπ-(hex-5-yn-1-yl)-l-histidine (11)
As previously reported [39], to a solution of trifluoromethanesulfonic anhydride (2.8 mL,
2.8 mmol) in CH2Cl2 (5.0 mL) was added a solution of hex-5-yn-1-ol (0.31 mL, 2.8 mmol) and N-
ethyl-N-isopropylpropan-2-amine (0.49 mL, 2.8 mmol, 1.0 M in CH2Cl2) in CH2Cl2 (10 mL) dropwise
under argon at
of (S)-2,4-dimethoxybenzyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(1-trityl-1H-imidazol-4-
yl)propanoate (10) [24] (2.0 g, 2.5 mmol) in CH2Cl2 (5.0 mL) at
78 ◦C and the mixture was allowed to
−
78 ◦C and the mixture was stirred at
−
78 ◦C (20 min). To this was added a solution
−
come to room temperature and stirred (overnight). The solvent was removed by evaporation and a
solution of TFA:TIS (10:1, 10 mL) was added and the mixture was stirred at room temperature (2 h). The
reaction mixture was concentrated and the resulting residue was purified by silica gel chromatography
to provide the title compound 11 as a colorless sticky oil (0.53 g, 46% yield). ESI-MS m/z: 458.2 (MH+).
3.2. Peptide Synthesis
3.2.1. General Solid-Phase Peptide Synthesis (SPPS)
As previously reported [26], the protected amino acids used were Fmoc-l-Thr(PO(OBzl)OH)-OH,
Fmoc-l-Ser(OtBu)-OH, Fmoc-l-Leu-OH, and Fmoc-l-Pro-OH (purchased from Novabiochem,
MilliporeSigma, Burlington, MA, USA). Peptides were synthesized on a NovaSyn® TGR resin
(Novabiochem Cat#. 855009) using standard Fmoc SPPS protocols in N-methyl-2-pyrrolidone (NMP).
Coupling reagents used were 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium
3-oxid hexafluorophosphate (HATU) (5.0 equivalents) and N,N-diisopropylethylamine (DIPEA)
(10 equivalents). Non-coded amino acid residues were coupled using 2.5 equivalents amino acids.
Deprotection was performed using 20% piperidine in DMF (15 min, twice). Amino-terminal acetylation
was performed using 1-acetylimidazole. Finished resins were washed with NMP, MeOH, CH2Cl2, and
Et2O, dried under vacuum and cleaved by treatment with a solution of TFA:H2O:TIS (95:2.5:2.5) (5 h).
The resin was removed by filtration, and the filtrate was concentrated under vacuum and the resulting
residue was dissolved in 50% aqueous acetonitrile (5 mL) and purified by reverse-phase HPLC as
outline above in General Synthetic Procedures.
3.2.2. Synthesis of Peptides 3a–3d and 4b Using On-resin Copper-catalyzed Alkyne-azide
Cycloaddition Reaction (CuAAC)
By sequential coupling, Fmoc-Thr(PO(OBzl)OH)-OH, Fmoc-Ser(OtBu)-OH, alkynyl-labelled
N(π)-alkylated Fmoc-His-OH (11) or Fmoc-l-propargylglycine (14), Fmoc-Leu-OH, and Fmoc-Pro-
OH were loaded onto NovaSyn® TGR resin using the general SPPS protocols outlined above. The
pre-loaded resin (12 or 15, 0.02 mmol) was mixed with a solution of azides (9a–9d or 16) (0.14 mmol),
copper(I) iodide (0.26 mmol), DIEA (0.34 mmol) and l-ascorbic acid (0.14 mmol) in BuOH:DMF:pyridine
(5:3:2, 1.5 mL) and the mixture was stirred (17 h). The resin was washed with NMP, MeOH, CH2Cl2, and
Et2O, dried under vacuum and then cleaved by treatment with a solution of TFA:H2O:TIS (95:2.5:2.5)
(5 h). The resin was removed by filtration and the filtrate was concentrated under vacuum and the
resulting residue was subjected to preparative HPLC purification.

Molecules 2019, 24, 1488
10 of 15
3.2.3. Synthesis of Peptide 4b Using On-resin Ruthenium-catalyzed Alkyne-azide Cycloaddition
Reaction (RuAAC)
According to literature [36,
49], pre-loaded alkyne-labeled NovaSyn® TGR resin 15 (0.049 mmol)
was mixed with Cp*RuCl(PPh3)2 [pentamethylcyclopentadienylbis(triphenylphosphine) ruthenium (II)
chloride] (0.049 mmol) in DMF (1.0 mL) at room temperature (1 h). A solution of (8-azidooctyl)benzene
(16) (56 mg, 0.24 mmol) in DMF (1.0 mL) was added and the mixture was stirred at room temperature
(24 h). The resulting dark brown resin was washed with NMP, MeOH, CH2Cl2, and Et2O, dried under
vacuum and cleaved by treatment with a solution of TFA:H2O:TIS (95:2.5:2.5) (5 h). The resin was
removed by filtration and the filtrate was concentrated under vacuum and the resulting residue was
purified by preparative HPLC.
3.2.4. Peptide Data
Peptide 3a. Linear gradient of 0% B to 80% B over 30 min, retention time = 16.0 min. ESI-MS m/z: 888.4
(MH+). HRMS calcd C39H59N11O11P(MH+), 888.4128; found, 888.4139.
Peptide 3b. Linear gradient of 0% B to 80% B over 30 min, retention time = 16.4 min. ESI-MS m/z: 906.4
(MH+). HRMS calcd C39H58FN11O11P (MH+), 906.4033; found, 906.4045.
Peptide 3c. Linear gradient of 0% B to 80% B over 30 min, retention time = 17.0 min. ESI-MS m/z: 940.3
(MH+). HRMS calcd C39H57ClFN11O11P (MH+), 940.3644; found, 940.3650.
Peptide 3d. Linear gradient of 0% B to 80% B over 30 min, retention time = 17.8 min. ESI-MS m/z: 998.2
(MH+). HRMS calcd C45H62FN11O12P(MH+), 998.4296; found, 998.4311.
Peptide 4b. Linear gradient of 0% B to 80% B over 30 min, retention time = 22.6 min. ESI-MS m/z: 864.4
(MH+). HRMS calcd C39H63N9O11P (MH+): 864.4379; found, 864.4365.
Peptide 13. Linear gradient of 0% B to 80% B over 30 min, retention time = 14.8 min. ESI-MS m/z: 755.3
(MH+). HRMS calcd C32H52N8O11P (MH+): 755.3488; found, 755.3497.
Peptide 17. Linear gradient of 0% B to 80% B over 30 min, retention time = 15.0 min. ESI-MS m/z: 633.2
(MH+). HRMS calcd C25H42N6O11P (MH+), 633.2644; found, 633.2625.
3.3. Determination of Binding Selectivity against the PBDs of Plks 1–3 Using Fluorescence Polarization
3.3.1. Expression and Purification of Isolated PBDs of Plks 1–3 for Fluorescence Polarization Assays
As previously reported [25,26,50], a plasmid encoding myc-tagged Plk1 PBD was purchased from
Addgene (Plasmid #41162, Watertown, MA, USA) [51]. Plasmids encoding the myc-tagged PBDs of
Plk2 and Plk3 were generous gifts from Prof. Erich Nigg (Univ. of Basel, Basel, Switzerland) [51].
~20 M HEK (human embryonic kidney)-293T cells (2
plasmid using TurboFect reagent. Following 24 h expression, cells were harvested, lysed in buffer
[phosphate buffered saline (PBS, pH 7.4) containing 0.5% NP-40 and protease/phosphatase inhibitor
×
15 cm plates) were transfected with each
cocktail] using freeze/thaw cycles (3
×
) and centrifuged at 12,500
g for 10 min at 4 ◦C. The supernatant
×
containing expressed protein was diluted into 8 mL of PBS (pH 7.4) containing protease/phosphatase
inhibitor cocktail. This protein solution was added to a 1 mL bed of myc-agarose resin (Thermo
Scientific, Waltham, MA, USA) and allowed to bind for 2 h at 4 ◦C with gentle rotation. The lysate
was eluted and the resin was washed 4 with 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
×
(HEPES) buffered saline (HBS) containing 0.05% Tween-20, 1 mM dithiothreitol (DTT) and 1 mM
ethylenediaminetetraacetic acid (EDTA). The bound PBD protein was then eluted with a 1 mg/mL
solution of myc peptide (EQKLISEEDL) in HBS + 1 mM DTT and 1 mM EDTA. The purified PBD
protein was dialyzed 5
cut-off (MWCO) filter (Sigma-Aldrich, St. Louis, MO, USA) fixed angle rotor at 7500
The concentration of the final protein solution was determined by absorbance at 280 nm and purity
×
with HBS + 1 mM DTT and 1 mM EDTA using a 10 kDa molecular weight
×
g, 4 ◦C, 10 min).

Molecules 2019, 24, 1488
11 of 15
was determined by SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) with
Coomassie staining.
3.3.2. Evaluation of Binding Affinities against the Isolated PBDs of Plk1, Plk2 and Plk3 Using
Fluorescence Polarization Assays
As previously reported [25
,
26
,
50], isolated PBD protein was diluted to a 2 working dilution in
×
assay buffer (HEPES-buffered saline with 0.05% Tween-20, 1 mM DTT, and 1 mM EDTA). The following
final protein concentrations used were: 80 nM for Plk1 PBD; 80 nM for Plk2 PBD and 130 nM for
Plk3 PBD. These concentrations represent the approximate Kd values determined for the respective
fluorescence polarization probe sequences. Inhibitors were serially diluted to generate 4
dilutions in assay buffer containing 4% DMSO. 20 L of 2 PBD solution was added to each well of a
384-well plate (0% binding controls received 20 L of assay buffer). 10 L of the 4 inhibitor solution
×
working
µ
×
µ
µ
×
(or DMSO blank) was added to corresponding wells and allowed to pre-incubate at RT for 30 min with
shaking. The following sequences were utilized as fluorescent probes: 5CF-GPMQSpTPLNG-NH2 for
Plk1 PBD; 5CF-GPMQTSpTPKNG-NH2 for Plk2 PBD and 5CF-PLATSpTPKNG-NH2 for Plk3 PBD [10].
Fluorescent probes were diluted to 40 nM (4 ) in assay buffer and then 10 µL was added to each
×
well. The plate was allowed to equilibrate at room temperature for (30 min) with shaking. The FP
was read using a BioTek Synergy 2 plate reader (BioTek, Winooski, VT, USA) with 485/20 excitation
and 528/20 emission. The FP values were obtained in triplicate and normalized to 100% (no inhibitor)
and 0% binding (no protein) controls. Normalized values were plotted versus concentration and
analyzed using non-linear regression in GraphPad Prism 8 (GraphPad Software, San Diego, CA, USA)
[log(inhibitor) vs. response-variable slope (four parameter) model]. IC50 values are presented in Table 1
and represent average ± standard error of the mean (SEM).
3.4. Evaluation of Binding Affinities against Full-length Plk1 Using ELISA Assays
3.4.1. Lysate Production for ELISA-based Inhibition Assay against Full Length Plk1
Assays were conducted as previously reported [25,26,50]. To summarize, a plasmid encoding
myc-tagged full-length Plk1 (Addgene, Plasmid #41160) [52] was transiently transfected into HEK
(human embryonic kidney)-293T cells using the TurboFect reagent (Thermo Scientific, Waltham, MA,
USA) according to manufacturer’s instructions. Following 48 h expression, cells were harvested,
lysed in buffer (PBS, pH 7.4 with 0.5% NP-40 and protease/phosphatase inhibitor cocktail) using
freeze/thaw cycles (3
×
) and centrifuged at 10,000
g for 10 min at 4 ◦C. The supernatant was removed to
×
provide a crude cytosolic lysate containing overexpressed, myc-tagged Plk1 (total protein concentration
determined by bicinchoninic acid (BCA) assay).
3.4.2. Determination of Inhibitory Potency in an ELISA Assay Using Full-Length Plk1
As previously reported [25
PMQS(pT)PLN-NH2) was diluted to 1
and loaded onto the wells of a 96-well Neutravidin-coated plate (Pierce Biotechnology, ThermoFisher
Scientific, Waltham, MA, USA) at 100 L per well for 1 h (background control contained no biotinylated
peptide). The wells were washed once with 150 L PBST (PBS, pH 7.4 + 0.05% Tween-20), and then
100 L of 1% BSA in PBS (pH 7.4) (blocking buffer) was added for 1 h. A cytosolic lysate-containing
transiently expressed myc-tagged Plk1 protein was diluted to 300 g/mL in PBS (pH 7.4) containing
protease/phosphatase inhibitors (Pierce Biotechnology), mixed with competitive inhibitor (from a
10 stock in ~4% DMSO/PBS), and allowed to pre-incubate for 1 h (100 L per well in a 96-well
plate, 30 g total protein). The blocked ELISA plate was washed 2 with PBST (PBS, pH 7.4 + 0.05%
Tween-20) (150 L) and the pre-incubated lysates were added to the plate and incubated (1 h). The
wells were washed 4 with PBST (150 L) and then treated with anti-myc primary antibody (1:1500
dilution in PBS, mouse monoclonal, Pierce Biotechnology) for 1 h. The wells were then washed 4
,
26,
50] a biotinylated phosphopeptide (sequence: Biotin-Ahx-
µM (from a 2 mM DMSO stock solution) in PBS (pH 7.4)
µ
µ
µ
µ
×
µ
µ
×
µ
×
µ
×

Molecules 2019, 24, 1488
12 of 15
with PBST (150
[1:3000 dilution in 1% (%w/v) BSA in PBS, Pierce Biotechnology] for 1 h. The wells were then washed 5
with PBST (150
L) and incubated with Turbo TMB (3,30,5,50-tetramethyl benzidine substrate)-ELISA
µL), and incubated with rabbit anti-mouse horseradish peroxidase (HRP) conjugate
×
µ
solution (Pierce Biotechnology) until the desired absorbance was reached (5–10 min). The reaction
was quenched by the addition of 2 N aqueous H2SO4 and the absorbance was measured at 450 nm
using a BioTek Synergy 2 96-well plate reader. Absorbance was plotted versus concentration (logM)
and fit to a non-linear regression analysis using GraphPad Prism 8 software [model: log(inhibitor) vs.
response-variable slope (four parameters)]. The calculated IC50 values presented in Table 2 are from
multiple independent experiments and were normalized and averaged to provide values ± SEM.
4. Conclusions
Presented herein are the design of the triazole-containing conformationally constrained peptides
3a–3d and the His mimic-containing peptide 4b as well as their facile preparation using on-resin
azide-alkyne cycloaddition reactions. The resulting peptides were evaluated in FP binding assays using
isolated PBDs of Plk1, Plk2 and Plk3 and in ELISA assays against full-length Plk1. Certain of these
new ligands retain the high Plk1 PBD-binding affinity of the parent peptide 2a, while having enhanced
selectivity for the PBD of Plk1 relative to the PBDs of Plk2 and Plk3. It is interesting that peptides 4b
and 3d show significantly greater than anticipated reduced affinities in full-length Plk1 ELISA assays
relative to values obtained with the isolated PBD (160-fold for 4b and 480-fold for 3d). The larger
differences may indicate a reduced ability of these triazole-containing peptides to effectively relieve
auto-inhibition arising from interdomain interactions between the KD and PBD or to engage the PBD
cryptic pocket in the full-length construct. These observations are noteworthy, in that they potentially
indicate structural interactions of the KD and PBD in full-length Plk1 that are not anticipated by the
previous co-crystal structure of isolated KD and PBD in the presence of Map205.
Supplementary Materials: Supplementary material associated with this article is available online. Figures S1 and
S2 reporting FP binding data against the isolated PBDs of Plk1, Plk2 and Plk3 and ELISA binding assays against
full-length Plk1.
Author Contributions: X.Z.Z. designed and synthesized the peptides. K.T. and D.H. performed the biological
evaluation. X.Z.Z., K.T., D.H. and T.R.B.Jr. interpreted the data and wrote the paper. All authors have approved
the final manuscript.
Funding: This work was supported by the Intramural Research Program of the NIH, Center for Cancer Research,
National Cancer Institute, National Institutes of Health. This work was supported in part by a JSPS Research
Fellowship for Japanese Biomedical and Behavioral Researchers at NIH.
Acknowledgments: We thank Joseph Barchi (Chemical Biology Laboratory, NCI, NIH) for helpful discussion
concerning NMR and James A. Kelley and Christopher C. Lai (Chemical Biology Laboratory, NCI, NIH) for
HRMS data.
Conflicts of Interest: The authors declare no conflict of interest.
References
1.
Zitouni, S.; Nabais, C.; Jana, S.C.; Guerrero, A.; Bettencourt-Dias, M. Polo-like kinases: Structural variations
lead to multiple functions. Nat. Rev. Mol. Cell Biol. 2014, 15, 433–452. [CrossRef] [PubMed]
Park, J.-E.; Erikson, R.L.; Lee, K.S. Feed-forward mechanism of converting biochemical cooperativity to
mitotic processes at the kinetochore plate. Proc. Natl. Acad. Sci. USA 2011, 108, 8200–8205. [CrossRef]
[PubMed]
2.
3.
4.
5.
Lowery, D.M.; Lim, D.; Yaffe, M.B. Structure and function of polo-like kinases. Oncogene 2005, 24, 248–259.
[CrossRef] [PubMed]
Strebhardt, K.; Ullrich, A. Targeting polo-like kinase 1 for cancer therapy. Nat. Rev. Cancer 2006, 6, 321–330.
[CrossRef]
Park, J.-E.; Soung, N.-K.; Johmura, Y.; Kang, Y.H.; Liao, C.; Lee, K.H.; Park, C.H.; Nicklaus, M.C.; Lee, K.S.
Polo-box domain: A versatile mediator of polo-like kinase function. Cell. Mol. Life Sci. 2010, 67, 1957–1970.
[CrossRef]

Molecules 2019, 24, 1488
13 of 15
6.
7.
8.
9.
Strebhardt, K. Multifaceted polo-like kinases: Drug targets and antitargets for cancer therapy. Nat. Rev. Drug
Discov. 2010, 9, 643–660. [CrossRef]
Lee, K.S.; Burke, T.R., Jr.; Park, J.-E.; Bang, J.K.; Lee, E. Recent advances and new strategies in targeting Plk1
for anticancer therapy. Trends Pharmacol. Sci. 2015, 36, 858–877. [CrossRef]
Archambault, V.; Lepine, G.; Kachaner, D. Understanding the polo kinase machine. Oncogene 2015, 34,
4799–4807. [CrossRef]
Jang, Y.-J.; Lin, C.-Y.; Ma, S.; Erikson, R.L. Functional studies on the role of the C-terminal domain of
mammalian polo-like kinase. Proc. Nat. Acad. Sci. USA 2002, 99, 1984–1989. [CrossRef]
10. Reindl, W.; Yuan, J.; Kraemer, A.; Strebhardt, K.; Berg, T. Inhibition of polo-like kinase 1 by blocking polo-box
domain-dependent protein-protein interactions. Chem. Biol. 2008, 15, 459–466. [CrossRef]
11. Reindl, W.; Graeber, M.; Strebhardt, K.; Berg, T. Development of high-throughput assays based on fluorescence
polarization for inhibitors of the polo-box domains of polo-like kinases 2 and 3. Anal. Biochem. 2009, 395,
189–194. [CrossRef]
12. Gjertsen, B.T.; Schoffski, P. Discovery and development of the polo-like kinase inhibitor volasertib in cancer
therapy. Leukemia 2015, 29, 11–19. [CrossRef]
13. Berg, A.; Berg, T. Inhibitors of the polo-box domain of polo-like kinase 1. ChemBioChem 2016, 17, 650–656.
[CrossRef]
14. Yun, S.-M.; Moulaei, T.; Lim, D.; Bang, J.K.; Park, J.-E.; Shenoy, S.R.; Liu, F.; Kang, Y.H.; Liao, C.; Soung, N.-K.;
et al. Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of
polo-like kinase 1. Nat. Struct. Mol. Biol. 2009, 16, 876–882. [CrossRef]
15. Liu, F.; Park, J.-E.; Qian, W.-J.; Lim, D.; Graber, M.; Berg, T.; Yaffe, M.B.; Lee, K.S.; Burke, T.R., Jr. Serendipitous
alkylation of a Plk1 ligand uncovers a new binding channel. Nat. Chem. Biol. 2011, 7, 595–601. [CrossRef]
16. Liu, F.; Park, J.-E.; Qian, W.-J.; Lim, D.; Scharow, A.; Berg, T.; Yaffe, M.B.; Lee, K.S.; Burke, T.R., Jr. Identification
of high affinity polo-like kinase 1 (Plk1) polo-box domain binding peptides using oxime-based diversification.
ACS Chem. Biol. 2012, 7, 805–810. [CrossRef]
17. Liu, F.; Park, J.-E.; Qian, W.-J.; Lim, D.; Scharow, A.; Berg, T.; Yaffe, M.B.; Lee, K.S.; Burke, T.R., Jr.
Peptoid-peptide hybrid ligands targeting the polo box domain of polo-like kinase 1. ChemBioChem 2012, 13,
1291–1296. [CrossRef]
18. Qian, W.-J.; Park, J.-E.; Grant, R.; Lai, C.C.; Kelley, J.A.; Yaffe, M.B.; Lee, K.S.; Burke, T.R., Jr. Neighbor-directed
histidine N(τ)–alkylation: A route to imidazolium-containing phosphopeptide macrocycles. Pept. Sci. 2015,
104, 663–673. [CrossRef]
19. Hymel, D.; Grant, R.A.; Tsuji, K.; Yaffe, M.B.; Burke, T.R., Jr. Histidine N(τ)-cyclized macrocycles as a new
genre of polo-like kinase 1 polo-box domain-binding inhibitors. Bioorg. Med. Chem. Lett. 2018, 28, 3202–3205.
[CrossRef]
20. Sledz, P.; Stubbs, C.J.; Lang, S.; Yang, Y.-Q.; McKenzie, G.J.; Venkitaraman, A.R.; Hyvoenen, M.; Abell, C.
From crystal packing to molecular recognition: Prediction and discovery of a binding site on the surface of
polo-like kinase 1. Angew. Chem. Int. Ed. Engl. 2011, 50, 4003–4006. [CrossRef]
´
21. Tan, Y.S.; Sledz´, P.; Lang, S.; Stubbs, C.J.; Spring, D.R.; Abell, C.; Best, R.B. Using ligand-mapping simulations
to design a ligand selectively trgeting a cryptic surface pocket of polo-like kinase 1. Angew. Chem. Int. Ed.
Engl. 2012, 51, 10078–10081. [CrossRef]
´
22. Sledz´, P.; Lang, S.; Stubbs, C.J.; Abell, C. High-throughput interrogation of ligand binding mode using a
fluorescence-based assay. Angew. Chem. Int. Ed. Engl. 2012, 51, 7680–7683. [CrossRef]
23. Elia, A.E.; Rellos, P.; Haire, L.F.; Chao, J.W.; Ivins, F.J.; Hoepker, K.; Mohammad, D.; Cantley, L.C.; Smerdon, S.J.;
Yaffe, M.B. The molecular basis for phosphodependent substrate targeting and regulation of Plks by the
polo-box domain. Cell 2003, 115, 83–95. [CrossRef]
24. Qian, W.-J.; Park, J.-E.; Lee, K.S.; Burke, T.R., Jr. Non-proteinogenic amino acids in the pThr-2 position of
a pentamer peptide that confer high binding affinity for the polo box domain (PBD) of polo-like kinase 1
(Plk1). Bioorg. Med. Chem. Lett. 2012, 22, 7306–7308. [CrossRef]
25. Zhao, X.Z.; Hymel, D.; Burke, T.R., Jr. Application of oxime-diversification to optimize ligand interactions
within a cryptic pocket of the polo-like kinase 1 polo-box domain. Bioorg. Med. Chem. Lett. 2016, 26,
5009–5012. [CrossRef]
26. Zhao, X.Z.; Hymel, D.; Burke, T.R., Jr. Enhancing polo-like kinase 1 selectivity of polo-box domain-binding
peptides. Bioorg. Med. Chem. 2017, 25, 5041–5049. [CrossRef]

Molecules 2019, 24, 1488
14 of 15
27. Angell, Y.L.; Burgess, K. Peptidomimetics via copper-catalyzed azide-alkyne cycloadditions. Chem. Soc. Rev.
2007, 36, 1674–1689. [CrossRef]
28. Yoo, B.; Shin, S.B.Y.; Huang, M.L.; Kirshenbaum, K. Peptoid macrocycles: Making the rounds with
peptidomimetic oligomers. Chem. Eur. J. 2010, 16, 5528–5537. [CrossRef]
29. Kappe, C.O.; Van der Eycken, E. Click chemistry under non-classical reaction conditions. Chem. Soc. Rev.
2010, 39, 1280–1290. [CrossRef]
30. Pedersen, D.S.; Abell, A. 1,2,3-Triazoles in peptidomimetic chemistry. Eur. J. Org. Chem. 2011, 13, 2399–2411.
[CrossRef]
31. Ahmad Fuaad, A.A.; Azmi, F.; Skwarczynski, M.; Toth, I. Peptide conjugation via CuAAC ‘click’ chemistry.
Molecules 2013, 18, 13148–13174. [CrossRef]
32. Das, R.; Majumdar, N.; Lahiri, A. A review on 1,3-dipolar cycloaddition reactions in bioconjugation and it’s
importance in pharmaceutical chemistry. Int. J. Res. Pharm. Chem. 2014, 4, 467–472. [CrossRef]
33. Fehlhammer, W.P.; Beck, W. Azide chemistry—An inorganic perspective, part II [3+2]-cycloaddition reactions
of metal azides and related systems. Z. Anorg. Allg. Chem. 2015, 641, 1599–1678. [CrossRef]
34. Johansson, J.R.; Beke-Somfai, T.; Said Stålsmeden, A.; Kann, N. Ruthenium-catalyzed azide alkyne
cycloaddition reaction: Scope, mechanism, and applications. Chem. Rev. 2016, 116, 14726–14768. [CrossRef]
[PubMed]
35. Barlow, T.M.A.; Tourw
and uncatalysed azide–alkyne cycloadditions (AACs). Eur. J. Org. Chem. 2017, 32, 4678–4694. [CrossRef]
36. Buysse, K.; Farard, J.; Nikolaou, A.; Vanderheyden, P.; Vauquelin, G.; Sejer Pedersen, D.; Tourw , D.; Ballet, S.
é, D.; Ballet, S. Cyclisation to form small, medium and large rings by use of catalysed
é
Amino triazolo diazepines (Ata) as constrained histidine mimics. Org. Lett. 2011, 13, 6468–6471. [CrossRef]
37. Chen, Y.; Li, Z.; Liu, Y.; Lin, T.; Sun, H.; Yang, D.; Jiang, C. Identification of novel and selective non-peptide
inhibitors targeting the polo-box domain of polo-like kinase 1. Bioorg. Chem. 2018, 81, 278–288. [CrossRef]
38. Appel, R. Tertiary phosphane/tetrachloromethane, a versatile reagent for chlorination, dehydration, and
phosphorus-nitrogen linkage. Angew. Chem. Int. Ed. Engl. 1975, 14, 801–811. [CrossRef]
39. Qian, W.; Liu, F.; Burke, T.R., Jr. Investigation of unanticipated alkylation at the N(pi) position of a
histidyl residue under Mitsunobu conditions and synthesis of orthogonally protected histidine analogues.
J. Org. Chem. 2011, 76, 8885–8890. [CrossRef]
40. Tornoe, C.W.; Christensen, C.; Meldal, M. Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific
copper(I)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. J. Org. Chem. 2002, 67, 3057–3064.
[CrossRef]
41. Rostovtsev, V.V.; Green, L.G.; Fokin, V.V.; Sharpless, K.B. A stepwise Huisgen cycloaddition process:
Copper(I)-catalyzed regioselective “ligation” of azides and terminal alkynes. Angew. Chem. Int. Ed. Engl.
2002, 41, 2596–2599. [CrossRef]
42. Tron, G.C.; Pirali, T.; Billington, R.A.; Canonico, P.L.; Sorba, G.; Genazzani, A.A. Click chemistry reactions
in medicinal chemistry: Applications of the 1,3-dipolar cycloaddition between azides and alkynes.
Med. Res. Rev. 2008, 28, 278–308. [CrossRef]
43. Zhang, L.; Chen, X.; Xue, P.; Sun, H.H.Y.; Williams, I.D.; Sharpless, K.B.; Fokin, V.V.; Jia, G.
Ruthenium-catalyzed cycloaddition of alkynes and organic azides. J. Am. Chem. Soc. 2005, 127, 15998–15999.
[CrossRef]
44. Rasmussen, L.K.; Boren, B.C.; Fokin, V.V. Ruthenium-catalyzed cycloaddition of aryl azides and alkynes.
Org. Lett. 2007, 9, 5337–5339. [CrossRef]
45. Creary, X.; Anderson, A.; Brophy, C.; Crowell, F.; Funk, Z. Method for assigning structure of 1,2,3-triazoles.
J. Org. Chem. 2012, 77, 8756–8761. [CrossRef]
46. Xu, J.; Shen, C.; Wang, T.; Quan, J. Structural basis for the inhibition of polo-like kinase 1. Nat. Struct. Mol.
Biol. 2013, 20, 1047–1053. [CrossRef]
47. Fish, P.V.; Ryckmans, T.; Stobie, A.; Wakenhut, F. [4-(Phenoxy)pyridin-3-yl]methylamines: A new class of
selective noradrenaline reuptake inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 1795–1798. [CrossRef]
48. Siebertz, K.D.; Hackenberger, C.P.R. Chemoselective triazole-phosphonamidate conjugates suitable for
photorelease. Chem. Commun. 2018, 54, 763–766. [CrossRef]
49. Boren, B.C.; Narayan, S.; Rasmussen, L.K.; Zhang, L.; Zhao, H.; Lin, Z.; Jia, G.; Fokin, V.V. Ruthenium-catalyzed
azide−alkyne cycloaddition: Scope and mechanism. J. Am. Chem. Soc. 2008, 130, 8923–8930. [CrossRef]

Molecules 2019, 24, 1488
15 of 15
50. Hymel, D.; Burke, T.R., Jr. Phosphatase-stable phosphoamino acid mimetics that enhance binding affinities
with the polo-box domain of polo-like kinase 1. ChemMedChem 2017, 12, 202–206. [CrossRef]
51. Hanisch, A.; Wehner, A.; Nigg, E.A.; Sillje, H.H.W. Different Plk1 functions show distinct dependencies on
polo-Box domain-mediated targeting. Mol. Biol. Cell 2006, 17, 448–459. [CrossRef]
52. Golsteyn, R.M.; Schultz, S.J.; Bartek, J.; Ziemiecki, A.; Ried, T.; Nigg, E.A. Cell cycle analysis and chromosomal
localization of human Plk1, a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces
cerevisiae Cdc5. J. Cell Sci. 1994, 107, 1509–1517.
Sample Availability: Samples of select peptides may be available from the authors in limited quantities.
©
2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).